Local 12: Chemotherapy in recurrent ovarian cancer patients
UC researcher publishes New England Journal of Medicine study looking at outcomes
The five-year survival rate for ovarian cancer is only 36%, one of the worst cancer survival rates out there.
Finding the right treatments, however, is critical to changing that survival rate, according to Dr. Thomas Herzog, a professor at UC and gynecologic oncologist with UC Health. His team just released a study in the New England Journal of Medicine comparing those who just had chemotherapy with a recurrent cancer and those who had chemotherapy in addition to surgery when the cancer came back.
Featured photo courtesy of Unsplash.
Related Stories
UC student leaders prioritize well-being, collaboration and spirit
April 28, 2026
Wilaini Alicea and Zohair Siddiqui were elected UC student body president and student body vice president in March. The two student leaders discuss their priorities for student government.
Emeriti professors make $1 million gift to UC’s College of Medicine
April 28, 2026
Henry A. Nasrallah’s life’s work has been focused on helping others. His vocation as a psychiatrist, researcher and educator is closely intertwined with his personal commitment to philanthropy, reflecting a deep dedication to improving psychiatric care, particularly by advancing research in neurobiology and treatments for schizophrenia and related disorders.
Hoxworth, FC Cincinnati celebrate life-saving donors with exclusive May giveaway
April 27, 2026
Hoxworth Blood Center, University of Cincinnati, is asking donors to score big for their community this May with an exclusive 40 oz. FC Cincinnati–themed tumbler available to donors at the seven neighborhood donor centers and select mobile drives while supplies last.